684 related articles for article (PubMed ID: 29429810)
21. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.
Pugach P; Ozorowski G; Cupo A; Ringe R; Yasmeen A; de Val N; Derking R; Kim HJ; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; Julien JP; Burton DR; Wilson IA; Sanders RW; Klasse PJ; Ward AB; Moore JP
J Virol; 2015 Mar; 89(6):3380-95. PubMed ID: 25589637
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
[TBL] [Abstract][Full Text] [Related]
23. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
[TBL] [Abstract][Full Text] [Related]
24. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
[TBL] [Abstract][Full Text] [Related]
25. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
Ma BJ; Alam SM; Go EP; Lu X; Desaire H; Tomaras GD; Bowman C; Sutherland LL; Scearce RM; Santra S; Letvin NL; Kepler TB; Liao HX; Haynes BF
PLoS Pathog; 2011 Sep; 7(9):e1002200. PubMed ID: 21909262
[TBL] [Abstract][Full Text] [Related]
26. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
Ringe R; Thakar M; Bhattacharya J
Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
[TBL] [Abstract][Full Text] [Related]
27. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
28. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
[TBL] [Abstract][Full Text] [Related]
29. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
30. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
31. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.
Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588
[TBL] [Abstract][Full Text] [Related]
32. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.
Ringe RP; Ozorowski G; Yasmeen A; Cupo A; Cruz Portillo VM; Pugach P; Golabek M; Rantalainen K; Holden LG; Cottrell CA; Wilson IA; Sanders RW; Ward AB; Klasse PJ; Moore JP
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381572
[TBL] [Abstract][Full Text] [Related]
33. Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.
Nadai Y; Held K; Joseph S; Ahmed MIM; Hoffmann VS; Peterhoff D; Missanga M; Bauer A; Joachim A; Reimer U; Zerweck J; McCormack S; Cope AV; Tatoud R; Shattock RJ; Robb ML; Sandstroem EG; Hoelscher M; Maboko L; Bakari M; Kroidl A; Wagner R; Weber J; Pollakis G; Geldmacher C
Front Immunol; 2019; 10():717. PubMed ID: 31105688
[No Abstract] [Full Text] [Related]
34. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
Alam SM; Cronin K; Parks R; Anasti K; Ding H; Go EP; Desaire H; Eaton A; Montefiori D; Sodroski J; Kappes J; Haynes BF; Saunders KO
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817216
[TBL] [Abstract][Full Text] [Related]
35. Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.
Kraft Z; Strouss K; Sutton WF; Cleveland B; Tso FY; Polacino P; Overbaugh J; Hu SL; Stamatatos L
J Virol; 2008 Jun; 82(12):5912-21. PubMed ID: 18400850
[TBL] [Abstract][Full Text] [Related]
36. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
37. Design and characterization of a germ-line targeting soluble, native-like, trimeric HIV-1 Env lacking key glycans from the V1V2-loop.
Ahmed S; Shrivastava T; Kumar R; Kumar M; Banerjee M; Kumar N; Bansal M; Das S; Samal S
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129733. PubMed ID: 32949621
[TBL] [Abstract][Full Text] [Related]
38. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.
Sellhorn G; Kraft Z; Caldwell Z; Ellingson K; Mineart C; Seaman MS; Montefiori DC; Lagerquist E; Stamatatos L
J Virol; 2012 Jan; 86(1):128-42. PubMed ID: 22031951
[TBL] [Abstract][Full Text] [Related]
39. Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.
Martinez-Murillo P; Tran K; Guenaga J; Lindgren G; Àdori M; Feng Y; Phad GE; Vázquez Bernat N; Bale S; Ingale J; Dubrovskaya V; O'Dell S; Pramanik L; Spångberg M; Corcoran M; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Immunity; 2017 May; 46(5):804-817.e7. PubMed ID: 28514687
[TBL] [Abstract][Full Text] [Related]
40. Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.
Morris CD; Azadnia P; de Val N; Vora N; Honda A; Giang E; Saye-Francisco K; Cheng Y; Lin X; Mann CJ; Tang J; Sok D; Burton DR; Law M; Ward AB; He L; Zhu J
mBio; 2017 Feb; 8(1):. PubMed ID: 28246356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
